Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pires D is a fixed-dose combination over-the-counter (OTC) cough and cold preparation developed and marketed by Navana Pharmaceuticals. It contains dextromethorphan (a centrally-acting cough suppressant), diphenhydramine (a first-generation antihistamine with antitussive and anticholinergic properties), and levomenthol (a cooling agent that soothes throat irritation). Together, these components work synergistically to provide relief from persistent, dry, irritating coughs and associated upper respiratory symptoms, while also aiding restful sleep.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextromethorphan + diphenhydramine + levomenthol.